“our expectation is that we will likely have a single phase three that will follow for each of APO one and APO two following these phase two data readouts that I just mentioned in '27”
→ Read the source episode
Avalon Pharma initiates Phase 3 clinical trials for APL1 and/or APO2 programs
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.